FIELD: medicine.
SUBSTANCE: clinical investigation is supplemented with simultaneously testing monoamine oxidase (MAO) activity in thrombocytes in nmole of benzaldehyde per 1 mg of protein an hour and semicarbazide-dependent amine oxidase (CAO) activity in blood serum in nmole of benzaldehyde per one ml of blood serum an hour. The blood serum CAO to thrombocyte MAO activity relation is calculated. If the value exceeds 0.6, a positive result of atypical antipsychotic drug treatment in schizophrenia is predicted.
EFFECT: more precise and objective prediction, reduced length of treatment in schizophrenics.
2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF ATYPICAL ANTIPSYCHOTIC DRUG TREATMENT RATES IN SHIZOPHRENICS | 2010 |
|
RU2425378C1 |
| METHOD FOR PREDICTING EFFECTIVENESS OF OLANZAPINE ATYPICAL ANTIPSYCHOTIC DRUG THERAPY IN SCHIZOPHRENIA PATIENTS | 2017 |
|
RU2680529C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF PATIENTS WITH SCHIZOPHRENIA | 2021 |
|
RU2775440C1 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN SCHIZOPHRENIC PATIENTS | 2014 |
|
RU2546021C1 |
| METHOD FOR PREDICTING THE EFFICIENCY OF TREATING RESIDUAL SCHIZOPHRENIA WITH ATYPICAL NEUROLEPTICS | 2006 |
|
RU2319155C2 |
| METHOD FOR PREDICTING THE EFFICIENCY OF TREATING PATIENTS WITH SCHIZOPHRENIA WITH ATYPICAL NEUROLEPTIC QUETIAPIN (SEROQUEL) | 2005 |
|
RU2289137C1 |
| METHOD OF EFFICIENCY FORECAST FOR RESIDUAL SHIZOPHRENIA TREATMENT BY ATYPICAL NEUROLEPTIC QUETIAPINE | 2007 |
|
RU2349918C1 |
| LABORATORY METHOD FOR DIAGNOSIS OF LEADING NEGATIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA | 2015 |
|
RU2578957C1 |
| PREDICTION METHOD OF THERAPY EFFECTIVENESS IN PATIENTS WITH PAROXYSMAL SCHIZOPHRENIA | 2016 |
|
RU2621266C1 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN DEPRESSIVE EPISODE | 2013 |
|
RU2530635C1 |
